Endocrinology, Vol 135, 1299-1306, Copyright © 1994 by Endocrine Society

ARTICLES

JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization

H Rui, JJ Lebrun, RA Kirken, PA Kelly and WL Farrar
Cytokine Molecular Mechanisms Section, Frederick Cancer Research and Development Center, National Cancer Institute, Maryland 21702.

Cytokines that interact with receptors of the hematopoietin super- family have recently been reported to stimulate receptor-associated JAK tyrosine kinases, including PRL activation of JAK2. Unlike other tyrosine kinases, none of the JAK kinases has thus far been implicated in oncogenesis, and their involvement in growth signaling has not been established. Using the PRL-dependent pre-T-cell line Nb2, the present study provided a link between bivalent dimerization of a hematopoietin receptor and activation of its associated JAK kinase, and demonstrated a strong positive correlation between the mitogenic potency of a series of bivalent anti-PRL receptor antibodies and the degree of induced tyrosine phosphorylation of JAK2. Antibody bivalency was required for JAK2 phosphorylation. Monovalent anti-PRL receptor Fab fragments alone were inactive, but their activity could be partially restored by cross- linking with bivalent anti-Fab antibodies. Additional evidence for antibody-induced receptor dimerization was provided by a bell-shaped dose-response curve for the most potent receptor agonist, monoclonal antibody T6. This phenomenon is typically seen at pharmacological concentrations of bivalent ligands, when bound ligand molecules fail to adjoin a second receptor due to occupancy. The present study provided functional support for a model of PRL receptor triggering by ligand- induced receptor homodimerization and subsequent activation of the associated tyrosine kinase JAK2.

This article has been cited by other articles:

				A. Dagvadorj, R. A. Kirken, B. Leiby, J. Karras, and M. T. Nevalainen Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo Clin. Cancer Res., March 1, 2008; 14(5): 1317 - 1324. [Abstract] [Full Text] [PDF]

				N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF]

				E. Cocolakis, M. Dai, L. Drevet, J. Ho, E. Haines, S. Ali, and J.-J. Lebrun Smad Signaling Antagonizes STAT5-mediated Gene Transcription and Mammary Epithelial Cell Differentiation J. Biol. Chem., January 18, 2008; 283(3): 1293 - 1307. [Abstract] [Full Text] [PDF]

				S.-H. Tan, A. Dagvadorj, F. Shen, L. Gu, Z. Liao, J. Abdulghani, Y. Zhang, E. P. Gelmann, T. Zellweger, Z. Culig, et al. Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells Cancer Res., January 1, 2008; 68(1): 236 - 248. [Abstract] [Full Text] [PDF]

				L. Rider, A. Shatrova, E. P. Feener, L. Webb, and M. Diakonova JAK2 Tyrosine Kinase Phosphorylates PAK1 and Regulates PAK1 Activity and Functions J. Biol. Chem., October 19, 2007; 282(42): 30985 - 30996. [Abstract] [Full Text] [PDF]

				S. L. Gadd and C. V. Clevenger Ligand-Independent Dimerization of the Human Prolactin Receptor Isoforms: Functional Implications Mol. Endocrinol., November 1, 2006; 20(11): 2734 - 2746. [Abstract] [Full Text] [PDF]

				Z. S. Nagy, H. Rui, S. M. Stepkowski, J. Karras, and R. A. Kirken A Preferential Role for STAT5, not Constitutively Active STAT3, in Promoting Survival of a Human Lymphoid Tumor J. Immunol., October 15, 2006; 177(8): 5032 - 5040. [Abstract] [Full Text] [PDF]

				J. F. Langenheim, D. Tan, A. M. Walker, and W. Y. Chen Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists Mol. Endocrinol., March 1, 2006; 20(3): 661 - 674. [Abstract] [Full Text] [PDF]

				S. L. Miller, J. E. DeMaria, D. O. Freier, A. M. Riegel, and C. V. Clevenger Novel Association of Vav2 and Nek3 Modulates Signaling through the Human Prolactin Receptor Mol. Endocrinol., April 1, 2005; 19(4): 939 - 949. [Abstract] [Full Text] [PDF]

				T. Ducret, A.-M. Vacher, and P. Vacher Effects of Prolactin on Ionic Membrane Conductances in the Human Malignant Astrocytoma Cell Line U87-MG J Neurophysiol, March 1, 2004; 91(3): 1203 - 1216. [Abstract] [Full Text] [PDF]

				N. Binart, N. Melaine, C. Pineau, H. Kercret, A. M. Touzalin, P. Imbert-Bollore, P. A. Kelly, and B. Jegou Male Reproductive Function Is Not Affected in Prolactin Receptor-Deficient Mice Endocrinology, September 1, 2003; 144(9): 3779 - 3782. [Abstract] [Full Text] [PDF]

				C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF]

				J. B. Kline, M. A. Rycyzyn, and C. V. Clevenger Characterization of a Novel and Functional Human Prolactin Receptor Isoform ({Delta}S1PRLr) Containing Only One Extracellular Fibronectin-Like Domain Mol. Endocrinol., October 1, 2002; 16(10): 2310 - 2322. [Abstract] [Full Text] [PDF]

				J.-L. Taupin, P. Legembre, J. Bitard, S. Daburon, V. Pitard, F. Blanchard, L. Duplomb, A. Godard, Y. Jacques, and J.-F. Moreau Identification of Agonistic and Antagonistic Antibodies against gp190, the Leukemia Inhibitory Factor Receptor, Reveals Distinct Roles for Its Two Cytokine-binding Domains J. Biol. Chem., December 14, 2001; 276(51): 47975 - 47981. [Abstract] [Full Text] [PDF]

				J. Frasor, K. Park, M. Byers, C. Telleria, T. Kitamura, L.-y. Yu-Lee, J. Djiane, O.-K. Park-Sarge, and G. Gibori Differential Roles for Signal Transducers and Activators of Transcription 5a and 5b in PRL Stimulation of ER{alpha} and ER{beta} Transcription Mol. Endocrinol., December 1, 2001; 15(12): 2172 - 2181. [Abstract] [Full Text] [PDF]

				S. Bernichtein, S. Kinet, S. Jeay, M. Llovera, D. Madern, J. A. Martial, P. A. Kelly, and V. Goffin S179D-Human PRL, a Pseudophosphorylated Human PRL Analog, Is an Agonist and Not an Antagonist Endocrinology, September 1, 2001; 142(9): 3950 - 3963. [Abstract] [Full Text] [PDF]

				A M Jacobi, W Rohde, H-D Volk, T Dorner, G-R Burmester, and F Hiepe Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls Ann Rheum Dis, March 1, 2001; 60(3): 242 - 247. [Abstract] [Full Text] [PDF]

				I. Olazabal, J. Muñoz, S. Ogueta, E. Obregón, and J. P. García-Ruiz Prolactin (PRL)-PRL Receptor System Increases Cell Proliferation Involving JNK (c-Jun Amino Terminal Kinase) and AP-1 Activation: Inhibition by Glucocorticoids Mol. Endocrinol., April 1, 2000; 14(4): 564 - 575. [Abstract] [Full Text]

				C. A. Peters, E. T. Maizels, M. C. Robertson, R. P.C. Shiu, M. S. Soloff, and M. Hunzicker-Dunn Induction of Relaxin Messenger RNA Expression in Response to Prolactin Receptor Activation Requires Protein Kinase C {delta} Signaling Mol. Endocrinol., April 1, 2000; 14(4): 576 - 590. [Abstract] [Full Text]

				M. A. RYCYZYN and C. V. CLEVENGER Role of Cyclophilins in Somatolactogenic Action Ann. N.Y. Acad. Sci., January 1, 2000; 917(1): 514 - 521. [Abstract] [Full Text] [PDF]

				A. M. NORFLEET, C. H. CLARKE, B. GAMETCHU, and C. S. WATSON Antibodies to the estrogen receptor-{alpha} modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors FASEB J, January 1, 2000; 14(1): 157 - 165. [Abstract] [Full Text]

				J. B. Kline, H. Roehrs, and C. V. Clevenger Functional Characterization of the Intermediate Isoform of the Human Prolactin Receptor J. Biol. Chem., December 10, 1999; 274(50): 35461 - 35468. [Abstract] [Full Text] [PDF]

				D. Coss, C. B. Kuo, L. Yang, P. Ingleton, R. Luben, and A. M. Walker Dissociation of Janus Kinase 2 and Signal Transducer and Activator of Transcription 5 Activation after Treatment of Nb2 Cells with a Molecular Mimic of Phosphorylated Prolactin Endocrinology, November 1, 1999; 140(11): 5087 - 5094. [Abstract] [Full Text]

				S. L. Wyszomierski, J. Yeh, and J. M. Rosen Glucocorticoid Receptor/Signal Transducer and Activator of Transcription 5 (STAT5) Interactions Enhance STAT5 Activation by Prolonging STAT5 DNA Binding and Tyrosine Phosphorylation Mol. Endocrinol., February 1, 1999; 13(2): 330 - 343. [Abstract] [Full Text]

				B. Deng, N. Banu, B. Malloy, P. Hass, J. F. Wang, L. Cavacini, D. Eaton, and H. Avraham An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis Blood, September 15, 1998; 92(6): 1981 - 1988. [Abstract] [Full Text] [PDF]

				D. Guo, J. D. Dunbar, C. H. Yang, L. M. Pfeffer, and D. B. Donner Induction of Jak/STAT Signaling by Activation of the Type 1 TNF Receptor J. Immunol., March 15, 1998; 160(6): 2742 - 2750. [Abstract] [Full Text] [PDF]

				S. W. Rowlinson, S. N. Behncken, J. E. Rowland, R. W. Clarkson, C. J. Strasburger, Z. Wu, W. Baumbach, and M. J. Waters Activation of Chimeric and Full-length Growth Hormone Receptors by Growth Hormone Receptor Monoclonal Antibodies. A SPECIFIC CONFORMATIONAL CHANGE MAY BE REQUIRED FOR FULL-LENGTH RECEPTOR SIGNALING J. Biol. Chem., February 27, 1998; 273(9): 5307 - 5314. [Abstract] [Full Text] [PDF]

				W.-P. Chang, Y. Ye, and C. V. Clevenger Stoichiometric Structure-Function Analysis of the Prolactin Receptor Signaling Domain by Receptor Chimeras Mol. Cell. Biol., February 1, 1998; 18(2): 896 - 905. [Abstract] [Full Text]

				V. J. Quijano Jr. and L. G. Sheffield Prolactin Decreases Epidermal Growth Factor Receptor Kinase Activity via a Phosphorylation-dependent Mechanism J. Biol. Chem., January 9, 1998; 273(2): 1200 - 1207. [Abstract] [Full Text] [PDF]

				H. Rui, J. Xu, S. Mehta, H. Fang, J. Williams, F. Dong, and P. M. Grimley Activation of the Jak2-Stat5 Signaling Pathway in Nb2 Lymphoma Cells by an Anti-apoptotic Agent, Aurintricarboxylic Acid J. Biol. Chem., January 2, 1998; 273(1): 28 - 32. [Abstract] [Full Text] [PDF]

				J. J. Berlanga, J. P. Garcia-Ruiz, M. Perrot-Applanat, P. A. Kelly, and M. Edery The Short Form of The Prolactin (PRL) Receptor Silences PRL Induction of the {beta}-Casein Gene Promoter Mol. Endocrinol., September 1, 1997; 11(10): 1449 - 1457. [Abstract] [Full Text]

				Y.-f. Wang, K. D. O’Neal, and L.-y. Yu-Lee Multiple Prolactin (PRL) Receptor Cytoplasmic Residues and Stat1 Mediate PRL Signaling to the Interferon Regulatory Factor-1 Promoter Mol. Endocrinol., August 1, 1997; 11(9): 1353 - 1364. [Abstract] [Full Text]

				T Hara and A Miyajima Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis Stem Cells, November 1, 1996; 14(6): 605 - 618. [Abstract]

				S. Kinet, V. Goffin, V. Mainfroid, and J. A. Martial Characterization of Lactogen Receptor-binding Site 1of Human Prolactin J. Biol. Chem., June 14, 1996; 271(24): 14353 - 14360. [Abstract] [Full Text] [PDF]

				N. B. Prevarskaya, R. N. Skryma, P. Vacher, N. Daniel, J. Djiane, and B. Dufy Role of Tyrosine Phosphorylation in Potassium Channel Activation J. Biol. Chem., October 13, 1995; 270(41): 24292 - 24299. [Abstract] [Full Text] [PDF]

				R. J. Duhé and W. L. Farrar Characterization of Active and Inactive Forms of the JAK2 Protein-tyrosine Kinase Produced via the Baculovirus Expression Vector System J. Biol. Chem., September 29, 1995; 270(39): 23084 - 23089. [Abstract] [Full Text] [PDF]

				C. V. Clevenger, W. Ngo, D. L. Sokol, S. M. Luger, and , A. M. Gewirtz Vav Is Necessary for Prolactin-stimulated Proliferation and Is Translocated into the Nucleus of a T-cell Line J. Biol. Chem., June 2, 1995; 270(22): 13246 - 13253. [Abstract] [Full Text] [PDF]